CFI-402257

01/01/2018 - "CFI-402257 induced apoptosis and potentiated aneuploidy in TNBC lines by accelerating progression through mitosis and inducing mitotic segregation errors. "
10/01/2019 - "CFI-402257 triggered aneuploidy and apoptotic death of lung cancer cells without changing centrosome number. "
01/01/2017 - "Human cancer cells treated with CFI-402257 exhibit effects consistent with Mps1 kinase inhibition, specifically SAC inactivation, leading to chromosome missegregation, aneuploidy, and ultimately cell death. "

01/01/2017 - "Our findings provide a rationale for the clinical evaluation of CFI-402257 in patients with solid tumors."
01/01/2022 - "Our mass cytometry data illustrated the dynamic changes in the tumor-infiltrating immune populations after treatment with CFI-402257. "
01/01/2017 - "Oral administration of CFI-402257 in monotherapy or in combination with an anti-programmed cell death 1 (PD-1) antibody in mouse models of human cancer results in inhibition of tumor growth at doses that are well-tolerated. "
01/01/2017 - "Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer."
01/01/2017 - "Human cancer cells treated with CFI-402257 exhibit effects consistent with Mps1 kinase inhibition, specifically SAC inactivation, leading to chromosome missegregation, aneuploidy, and ultimately cell death. "

10/01/2019 - "Future work should determine whether CFI-402257 treatment alone or with a MAPK inhibitor is active in the lung cancer clinic."
10/01/2019 - "CFI-402257 triggered aneuploidy and apoptotic death of lung cancer cells without changing centrosome number. "

01/01/2022 - "CFI-402257, a TTK inhibitor, effectively suppresses hepatocellular carcinoma."

01/01/2022 - "These findings nominate the TTK inhibitor CFI-402257 as a therapeutic strategy for a defined subset of ER+ breast cancer patients who develop resistance to CDK4/6i."